Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV.

Saved in:
Bibliographic Details
Title: Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV.
Authors: Tsirizani L; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Training and Research Unit of Excellence, Kamuzu University of Health Sciences, Blantyre, Malawi., Waalewijn H; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Szubert A; Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom., Mulenga V; Department of Paediatrics and Child Health, University of Zambia, School of Medicine, Lusaka, Zambia., Chabala C; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Department of Paediatrics and Child Health, University of Zambia, School of Medicine, Lusaka, Zambia.; University Teaching Hospital, Lusaka, Zambia., Bwakura-Dangarembizi M; University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.; University of Zimbabwe Faculty of Medicine and Health Sciences, Department of Child, Adolescent and Women's Health, Harare, Zimbabwe., Chitsamatanga M; University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe., Rutebarika DA; Department of Paediatrics, joint Clinical Research Centre, Kampala, Uganda., Musiime V; Department of Paediatrics, joint Clinical Research Centre, Kampala, Uganda.; Department of Paediatrics and Child Health, Makerere University, College of Health Sciences, School of Medicine, Kampala, Uganda., Kasozi M; Department of HIV Research, joint Clinical Research Centre, Mbarara, Uganda., Lugemwa A; Department of HIV Research, joint Clinical Research Centre, Mbarara, Uganda., McIlleron HM; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Burger DM; Department of Pharmacy, Radboudumc Research Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, the Netherlands., Gibb DM; Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom., Colbers A; Department of Pharmacy, Radboudumc Research Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, the Netherlands., Denti P; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Wasmann RE; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Corporate Authors: CHAPAS-4 trial team
Source: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2025 Nov 05; Vol. 69 (11), pp. e0077125. Date of Electronic Publication: 2025 Sep 26.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1098-6596
DOI:10.1128/aac.00771-25